

25 October 2023

The Use of Biologic Medicines in Gastroenterology

I have a freedom of information query regarding the use of Biologic medicines in gastroenterology. Could you please answer the following two questions?

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs?

- Adalimumab – Humira 30
- Adalimumab Biosimilar 350
- Filgotinib 7
- Golimumab 10
- Infliximab – Remicade
- Infliximab Biosimilar 350 combined
- Mirikizumab 0
- Ozanimod 1
- Risankizumab 2
- Tofacitinib 8
- Upadacitinib 10
- Ustekinumab 190
- Vedolizumab 180

Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab – Humira 2
- Adalimumab Biosimilar 100
- Filgotinib 7
- Golimumab 10
- Infliximab - Remicade
- Infliximab Biosimilar 120 combined
- Mirikizumab 0
- Ozanimod 1
- Risankizumab 0
- Tofacitinib 8
- Upadacitinib 2
- Ustekinumab 25
- Vedolizumab 140